Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Neoadjuvant Trial of Selective Internal Yttrium-90 Radioembolization (SIRT) With Tremelimumab and Durvalumab (MEDI4736) for Resectable Hepatocellular Carcinoma

NCT05701488 is registered in ClinicalTrials.gov with Jiping Wang, MD, PhD as lead sponsor.

NCT NCT05701488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05701488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Neoadjuvant Trial of Selective Internal Yttrium-90 Radioembolization (SIRT) With Tremelimumab and Durvalumab (MEDI4736) for Resectable Hepatocellular Carcinoma
Lead sponsor
Jiping Wang, MD, PhD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 21, 2023
Completion date
October 1, 2026
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular cancer, hepatocellular carcinoma, resectable hepatocellular carcinoma